Skip to main content
logo
CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.8400
-0.0121 (-1.42%)
At close: Aug 5, 2026, 4:00 PM EDT
0.8618
+0.0218 (2.60%)
Pre-market: Aug 6, 2026, 8:11 AM EDT

CytoMed Therapeutics Income Statement

Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.320.07---
Revenue Growth
366.74%----
Cost of Revenue
0.070.02---
Gross Profit
0.260.05---
Selling, General & Admin
0.930.620.450.210.17
Depreciation & Amortization Expenses
0.230.120.10.110.1
Research & Development
2.221.911.591.521.09
Other Operating Expenses
0.990.211.410.010.36
Total Operating Expenses
4.372.873.561.851.72
Operating Income
-4.11-2.81-3.56-1.85-1.72
Interest Income
-0.010.01-0.03-0.03-0.21
Interest Expense
-0.02-0.02-0.05-0.13-0.12
Other Non-Operating Income (Expense)
0.140.3-0.49-1.120
Total Non-Operating Income (Expense)
0.110.29-0.58-1.28-0.33
Pretax Income
-4-2.52-4.13-3.13-2.05
Provision for Income Taxes
--00-
Net Income
-4-2.52-4.13-3.13-2.05
Minority Interest in Earnings
-0.02-0.01-0-0-0
Net Income to Common
-3.98-2.52-4.13-3.13-2.05
Net Income Growth
-----
Shares Outstanding (Basic)
12121188
Shares Outstanding (Diluted)
12121188
Shares Change
0.93%8.56%34.30%-34.21%
EPS (Basic)
-0.34-0.22-0.39-0.40-0.40
EPS (Diluted)
-0.34-0.22-0.39-0.40-0.40
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-4.34-4.11-3.59-1.87-2.3
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-0.37-0.36-0.34-0.24-0.29
Gross Margin
79.04%75.37%---
Operating Margin
-1266.81%-4047.22%---
Profit Margin
-1231.97%-3628.52%---
FCF Margin
-1336.46%-5913.81%---
EBITDA
-3.71-2.48-3.18-1.46-1.39
EBITDA Margin
-1143.01%-3564.69%---
EBIT
-4.11-2.81-3.56-1.85-1.72
EBIT Margin
-1266.81%-4047.22%---
Effective Tax Rate
0.00%0.00%-0.02%-0.05%0.00%
SEC Filings: 10-K · 10-Q